Spondyloarthritis & psoriatic arthritis
External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomized clinical trials of ixekizumab
Authors' conclusion
The altASDAS was truthful and discriminative in an external cohort and as such has been fully validated to be used in cases when PGA is unavailable.
Study context
- Population
- Radiographic/non-radiographic axSpA patients enrolled in the COAST trials of ixekizumabpooled COAST-V, -W, -X
- Participants
- 958 patients
- Comparison
- altASDAS vs ASDAS
- Outcome
- Truth: agreement of altASDAS with ASDAS
Methodological detailspooled analysis of three randomised controlled trials, external validation, OMERACT filter 2.0, pooled cohorts of COAST-V, -W, -X trials of ixekizumab
- Pooled analysis of three randomised controlled trials
- External validation
- OMERACT filter 2.0
- Pooled cohorts of COAST-V, -W, -X trials of ixekizumab
Performance
As reported in the abstract
MD (95% CI)
Between altASDAS and ASDASinterval is 95% limits of agreement
0.03(−0.31-0.24)
- altASDAS vs ASDAS · very good agreement
- ICC 0.99
- altASDAS vs ASDAS
- κ (disease activity (DA) states) 0.91
Further findings
| Outcome | κ CII |
|---|---|
| Discrimination: agreement with ASDAS response | 0.93 |
Discrimination: agreement with ASDAS response
- altASDAS discriminated between DA states (anchor: nocturnal pain >6/10)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomized clinical trials of ixekizumab. Rheumatology (Oxford). Published 25 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →